Neovacs issues €0.4 million in bonds

On July 3, 2025, Neovacs announced the issuance of €0.4 million in straight bonds, the first step in an equitization program. This issuance is fully underwritten by a management trust. Established since June 2023, the trust's mission is to convert the Bonds Reimbursable into Shares (ORA) into Neovacs shares and then sell these shares. It must also subscribe to straight bond issues of up to €4 million in total.

This financial strategy, aimed at optimizing financing, has already raised €1.8 million through the ORAs, corresponding to the creation of more than one billion shares. The latest drawdown could result in the issuance of 175 million new shares. The stake of existing shareholders is significantly diluted, from 1% to 0.73% for one of them.